Literature DB >> 1821257

The nucleus basalis of Meynert, senile plaques, and intellectual impairment in schizophrenia.

R S el-Mallakh1, D G Kirch, R Shelton, K J Fan, G Pezeshkpour, S Kanhouwa, R J Wyatt, J E Kleinman.   

Abstract

The large, hyperchromic, cholinergic neurons of the nucleus basalis of Meynert (nbM) and the presence of senile plaques were quantified in postmortem brain tissue from 10 intellectually impaired schizophrenic patients, seven intellectually intact schizophrenic patients, seven control subjects, and three patients with Alzheimer's disease. The two groups of schizophrenic patients did not show any significant differences when compared with the control group in nbM cell density or in plaque frequency. The Alzheimer's disease patients showed the expected decrease in nbM neuronal density and increase in plaques compared with the controls. The data suggest that compromised cognitive function in schizophrenia is not associated with diffuse neuropathology of the basal forebrain cholinergic system.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1821257     DOI: 10.1176/jnp.3.4.383

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  8 in total

Review 1.  The treatment of cognitive impairment in schizophrenia.

Authors:  Donald C Goff; Michele Hill; Deanna Barch
Journal:  Pharmacol Biochem Behav       Date:  2010-11-27       Impact factor: 3.533

2.  Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial.

Authors:  Oliver Freudenreich; Lawrence Herz; Thilo Deckersbach; A Eden Evins; David C Henderson; Corinne Cather; Donald C Goff
Journal:  Psychopharmacology (Berl)       Date:  2005-10-14       Impact factor: 4.530

Review 3.  Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy.

Authors:  Florian Ferreri; Catherine Agbokou; Serge Gauthier
Journal:  J Psychiatry Neurosci       Date:  2006-11       Impact factor: 6.186

Review 4.  Neurodegenerative model of schizophrenia: Growing evidence to support a revisit.

Authors:  William S Stone; Michael R Phillips; Lawrence H Yang; Lawrence S Kegeles; Ezra S Susser; Jeffrey A Lieberman
Journal:  Schizophr Res       Date:  2022-03-25       Impact factor: 4.662

Review 5.  Β-Amyloid Burden is Not Associated with Cognitive Impairment in Schizophrenia: A Systematic Review.

Authors:  Jun Ku Chung; Shinichiro Nakajima; Eric Plitman; Yusuke Iwata; Danielle Uy; Philip Gerretsen; Fernando Caravaggio; M Mallar Chakravarty; Ariel Graff-Guerrero
Journal:  Am J Geriatr Psychiatry       Date:  2016-04-29       Impact factor: 4.105

6.  Lack of association between schizophrenia and the apolipoprotein E epsilon 4 allele.

Authors:  E Jönsson; L Lannfelt; B Engvall; G Sedvall
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1996       Impact factor: 5.270

Review 7.  Molecular targets for treating cognitive dysfunction in schizophrenia.

Authors:  John A Gray; Bryan L Roth
Journal:  Schizophr Bull       Date:  2007-07-07       Impact factor: 7.348

8.  Lower cholinergic basal forebrain volumes link with cognitive difficulties in schizophrenia.

Authors:  Mihai Avram; Michel J Grothe; Lena Meinhold; Claudia Leucht; Stefan Leucht; Stefan Borgwardt; Felix Brandl; Christian Sorg
Journal:  Neuropsychopharmacology       Date:  2021-06-29       Impact factor: 7.853

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.